High glucose macrophage exosomes enhance atherosclerosis by driving cellular proliferation & hematopoiesis

Glycolysis
Cell proliferation
Hematopoiesis

Atherosclerotic plaque
Exosomes
Hyperglycemic environment

Laura Bouchareychas, Phat Duong, Tuan Anh Phu, ..., Warren J. Gasper, Kendall Van Keuren-Jensen, Robert L. Raffai
robert.raffai@ucsf.edu

Highlights
Macrophages cultured in high glucose (HG) produce pro-atherogenic exosomes
HG exosomes drive glycolysis in recipient macrophages & monocytosis in Apoe"−/−" mice
HG macrophage exosomes & human diabetic PAD plasma EVs are rich in miR-486-5p
High glucose macrophage exosomes enhance atherosclerosis by driving cellular proliferation & hematopoiesis

Laura Bouchareychas,1,2 Phat Duong,2 Tuan Anh Phu,2 Eric Alsop,3 Bessie Meechoovet,3 Rebecca Reiman,3 Martin Ng,2 Ryo Yamamoto,4,5 Hiromitsu Nakauchi,4,5 Warren J. Gasper,1,6 Kendall Van Keuren-Jensen,3 and Robert L. Raffai1,2,6,7,*

SUMMARY
We investigated whether extracellular vesicles (EVs) produced under hyperglycemic conditions could communicate signaling to drive atherosclerosis. We did so by treating Apoe−/− mice with exosomes produced by bone marrow-derived macrophages (BMDM) exposed to high glucose (BMDM–HG-exo) or control. Infusions of BMDM–HG-exo increased hematopoiesis, circulating myeloid cell numbers, and atherosclerotic lesions with an accumulation of macrophage foam and apoptotic cells. Transcriptome-wide analysis of cultured macrophages treated with BMDM–HG-exo or plasma EVs isolated from subjects with type II diabetes revealed a reduced inflammatory state and increased metabolic activity. Furthermore, BMDM–HG-exo induced cell proliferation and reprogrammed energy metabolism by increasing glycolytic activity. Lastly, profiling microRNA in BMDM–HG-exo and plasma EVs from diabetic subjects with advanced atherosclerosis converged on miR-486-5p as commonly enriched and recognized in dysregulated hematopoiesis and Abca1 control. Together, our findings show that EVs serve to communicate detrimental properties of hyperglycemia to accelerate atherosclerosis in diabetes.

INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death in the United States, with a predicted increase incidence in the coming decades (Xu et al., 2016). Patients with diabetes mellitus have a substantially elevated risk of coronary, cerebral, and peripheral atherosclerosis where hyperglycemia is the hallmark of the disease (Creager et al., 2003).

Diabetes predisposes to vulnerable atherosclerotic plaques associated with larger foam cell-rich and necrotic core sizes, a greater extent of smooth muscle cell and macrophage apoptosis, and a higher content of inflammatory cell infiltrate compared to nondiabetic atherosclerotic plaques (Burke et al., 2004).

While numerous metabolic disturbances associated with diabetes participate in accelerating atherosclerosis, hyperglycemia is recognized as a central contributor (Creager et al., 2003). Specifically, hyperglycemia is recognized to increase bone marrow (BM) hematopoiesis, and thereby levels of monocytes and neutrophils that readily enter lesions of atherosclerosis prone mice and increase macrophage burden that accelerates atherosclerosis (Flynn et al., 2020; Nagareddy et al., 2013). Lowering blood glucose levels in diabetic mice, including through SGLT2i and insulin mimetic peptide treatment, has recently been shown to reduce BM hematopoiesis and delay atherosclerosis (Kanter et al., 2018; Nagareddy et al., 2013). Collectively, these studies underscore the influence that hyperglycemia exerts on hematopoiesis to drive myelopoiesis and thereby exacerbate atherosclerosis in diabetes. Among cells of the immune system that participate in the process of atherosclerosis, monocytes and macrophages are recognized for their pivotal role in driving accelerated atherosclerosis in diabetes (Kanter et al., 2020; Moreno et al., 2000).

The discovery of extracellular vesicles (EVs) has opened new perspectives in the understanding of complications in diabetes including atherosclerosis. EVs are small bilayer membrane vesicles (30–2000 nm)
generated by all cell types and are present in all biological fluids (Mathieu et al., 2019). Exosomes with a size range from 30 to 150 nm are among one type of EVs that have emerged as important mediators of intercellular communication by transporting cargo that include mRNAs, microRNAs, proteins, and lipids (Thery et al., 2009; Valadi et al., 2007; Wen et al., 2018) within local or remote tissues. Numerous studies have now reported on circulating EVs including exosomes with dysregulated microRNA contents among patients with CVD and diabetes, making them useful biomarkers for monitoring disease progression (Freeman et al., 2018; Garcia-Contreras et al., 2017; Lakhter and Sims, 2015; Sorrentino et al., 2020).

Findings from our laboratory recently demonstrated that modulating cultured macrophages toward an anti-inflammatory phenotype fostered the release of exosomes with anti-inflammatory function capable of controlling diet-induced hematopoiesis and atherosclerosis in mice (Bouchareychas et al., 2020). Results of that study support the possibility that exosomes produced by macrophages exposed to metabolic stressors could potentiate atherosclerosis. Thus, our study was designed to investigate cell signaling properties of exosomes produced by macrophages cultured under high glucose conditions.

Our findings show that macrophage exosomes produced in a hyperglycemic environment promote metabolic reprogramming and cellular proliferation that drives hematopoiesis, myelopoiesis, and atherosclerosis in mice. Our data further show that human diabetic plasma EVs profoundly alter transcriptional programs and dysregulated mitochondrial activity when co-cultured with human macrophages. Together, our findings point to exosomes as perpetrators of hyperglycemia in driving the pathogenesis of diabetic atherosclerosis.

RESULTS
Assessment of exosomes produced by macrophages cultured in a high glucose environment

In this study, we sought to test the central hypothesis that hyperglycemia causes macrophages to produce exosomes that exert adverse effects in the cardiovascular system. To this end, we cultured BMDM with elevated glucose levels (25 mM glucose) or osmotic normal glucose levels (5.5 mM glucose +19.5 mM mannitol) for 24 h. We verified that the concentration of glucose in the medium remained elevated throughout the 24-h incubation period (Figure S1A).

We then used the dyes CM-H2DCFDA and CellROX to assess ROS production levels in the cells. Our findings shown that culturing BMDM in 25 mM glucose for a period of 24 h substantially increases CM-H2DCFDA levels (Figure S1B) and CellROX signals (Figure S1C). Next, using the MitoSox marker we found that high glucose increases superoxide produced by the mitochondria (Figure S1D). These data confirm that 25mM glucose led to cytosolic and mitochondrial ROS production in cultured primary macrophages. Next, we performed unbiased RNA sequencing analysis of BMDM cultured in high and normal glucose concentrations. We observed that 2,142 genes were differentially regulated by an exposure to high glucose, including 1,196 genes that were upregulated and 946 genes downregulated in high glucose compared to the normoglycemic condition (Figure S1E). Pathway analysis revealed an upregulation of genes implicated in immune responses, oxidative stress, and phagocytosis. Downregulated pathways were generally associated with metabolic processes (Figure S1F).

To examine the impact of metabolic stress in BMDM on their exosomes, we collected them from the conditioned culture medium of BMDM exposed to high concentrations of glucose (BMDM–HG-exo) or normal glucose levels (BMDM–NG-exo) using our recently described C-DGUC approach (Duong et al., 2019). Using NanoSight analysis, we observed a similar particle concentration (Figures 1A and 1B) relatively homogeneous in size (average mode size 77.51 ±3.33 nm for BMDM–NG-exo and 78.92 ±3.99 nm for BMDM–HG-exo) (Figure 1C) that fall within the average range of exosome size. Assessment of protein concentrations of the BMDM exosomes revealed similar levels in both conditions (Figure 1D) and the exosome secretion rate by cells cultured in normoglycemic or hyperglycemic concentration (Figure 1E). We next validated the purity of our exosome preparations by Western blot analysis. We confirmed the absence of non-exosomal markers (GM130 and Calnexin) and the presence of proteins known to be enriched in exosomes (Alix, Flotillin, CD81, and CD9) (Figure 1F). Subsequently, we validated the integrity of the exosomes by transmission electron microscopy (Figure 1G). Lastly, PKH26-labelled BMDM–NG-exo and BMDM–HG-exo were found to be endocytosed at a similar internalization efficiency in recipient BMDM (Figures 1H and 1I).
Figure 1. Assessment of exosomes produced by macrophages cultured in a high-glucose environment

(A) Representative size and concentration distribution of BMDM–NG-exo or BMDM–HG-exo purified from BMDM conditioned cell culture supernatants after a 24 h period of culture. Measurement of particle concentration (B) and particle mode size (C) using nanoparticle tracking analysis.

(D) Quantification of protein concentration by qubit assay.

(E) Calculation of secreted particles amounts per million of BMDM in high glucose or low glucose conditions.

(F) Western blot analysis of GM130, Calnexin, Alix, Flotillin, and CD81 and CD9 in exosome-free media (EFM), cell lysate, and BMDM–derived exosomes (representative of three independent experiments). An equal volume (37.5 μL) of cDGUC fraction samples was loaded for exosomes analysis and 10 μg of protein was loaded for the cell lysate sample.

(G) Electron micrograph of purified exosomes from BMDM cells. Scale bars: 100 nm.
We detected a similar magnitude in the expansion of the CMP and GMP populations in the BM of Apoe−/− mice fed a chow diet. Cohorts of these Apoe−/− mice were injected intra-peritoneally (IP) with 1×10^10 BMDM exosomes or saline (PBS) three times a week for four weeks. We chose an IP over an intravenous (IV) route for exosome infusions as we found this site to be both more practical and similarly effective in delivering exosomes into the circulation after 24 hr (Figure S1A). Importantly, repeated IP exosome treatments did not impact plasma cholesterol levels that remained an average of 445 mg/dL in Apoe−/− mice fed a chow diet (Figure S2B) and 1370 mg/dL for Apoe−/− mice fed a Western diet (Figure S2C).

Turning next to an assessment of splenic hematopoiesis, we noted that repeated injections of BMDM–HG-exo into Apoe−/− mice fed a chow diet led to robust increases in circulating leukocytes as assessed by flow cytometry compared to PBS injected mice. Control mice remained an average of 445 mg/dL in Apoe−/− mice fed a chow diet injected with BMDM–HG-exo. Specifically, we detected significant expansions of the common myeloid progenitor (CMP) and granulocyte-macrophage progenitor (GMP) cells (Figures 2A and 2B) in the BM compared to PBS injected control mice. In contrast, we found that injections of BMDM–HG-exo to Apoe−/− mice fed a chow diet that led to marked changes in hematopoiesis as assessed by flow cytometry when compared to mice injected with PBS but not BMDM–NG-exo. Specifically, we detected significant expansions of the common myeloid progenitor (CMP) and granulocyte-macrophage progenitor (GMP) cells (Figures 2A and 2B) in the BM compared to PBS injected control mice.

We noted no changes in megakaryocyte-erythroid progenitor (MEP) populations in either condition.

BMDM–HG-exosomes increase hematopoiesis and myeloid cell supply

Because hyperglycemia promotes the proliferation and differentiation of hematopoietic stem and progenitor cells (HSPCs) in the BM and spleen, we tested whether BMDM–HG-exo can communicate hyperglycemia-induced hematopoiesis in non-diabetic Apoe−/− mice fed a chow diet. In contrast, such marked expansion of progenitor cell populations caused by BMDM–HG-exo were not apparent in Apoe−/− mice fed a Western diet (Figure 2E). Similarly, an assessment of circulating leukocytes by flow cytometry revealed that repeated injections of BMDM–HG-exo compared to PBS and BMDM–NG-exo led to an increase among circulating Ly-6Chigh monocytes and neutrophils only in Apoe−/− mice fed a chow diet (Figures 2F and 2G). An analysis of myeloid cell populations in Apoe−/− mice fed a Western diet showed no differences in monocyte subtypes and neutrophils after repeated injections of BMDM exosomes (Figure 2H), which could in part be due to overwhelming proliferative signaling caused by hyperlipidemia in this model (Swirski et al., 2007; Yvan-Charvet et al., 2010). Taken together, our findings revealed that BMDM–HG-exo can modulate both BM and extramedullary hematopoiesis to augment leukocyte supply in the circulation of Apoe−/− mice fed a chow diet.

BMDM–HG-exo accelerate spontaneous and diet-induced atherosclerosis in Apoe−/− mice

As increased myelopoiesis is recognized to contribute to atherosclerotic plaque progression (Murphy et al., 2011; Robbins et al., 2012; Swirski et al., 2007), we tested whether BMDM–HG-exo can impact the course of atherogenesis in Apoe−/− mice fed a chow or Western diet. We did so through injections at a dose of 1×10^10 particles, three times a week for 4 weeks, a dose of exosomes that represent 4.5% of normal circulating exosomes levels (Huang et al., 2018). Interestingly, while injections of BMDM–HG-exo caused increased myelopoiesis only in chow-fed Apoe−/− mice, they accelerated atherosclerosis in the aortic root of both groups of mice compared to mice injected with controls (Figures 3A–3C). This acceleration of atherosclerosis by BMDM–HG-exo occurred in part by an increase in the number of lesional macrophages as detected by MOMA-positive immunofluorescent staining in Apoe−/− fed a chow diet (Figures 3D and 3E) and in Apoe−/− fed a Western diet (Figure 3F) as compared to mice treated with saline or BMDM–NG-exo. In contrast, measurements of the necrotic core area (Figure 3G) showed no significant impact of the BMDM-exo both in chow (Figure 3H) and Western diet fed (Figure 3I) Apoe−/− mice. However, when looking at cellular apoptotic events in the lesions by cleaved caspase 3 staining (Figure 3I), we noted markedly increased staining in lesions of Apoe−/− fed a chow diet injected with BMDM–HG-exo.
Figure 2. BMDM–HG-exosomes increase hematopoiesis and myeloid cell supply
(A) Representative plots of flow cytometric analyses showing the gating strategy for hematopoietic stem and progenitor cells in the BM of Apoe<sup>−/−</sup> mice fed a chow diet injected with PBS, BMDM–NG-exo or BMDM–HG-exo (1 x 10<sup>10</sup> particles/mice every two days) for 4 weeks. LSK cells were defined as Lin<sup>−</sup>–Sca<sup>1</sup>–c-Kit<sup>−</sup> (LK) CD41<sup>−</sup>CD34<sup>−</sup>CD16/32<sup>−</sup>. CMP give rise to granulocyte/macrophage progenitors (GMPs) gated as LK CD41<sup>−</sup>CD34<sup>−</sup>CD16/32<sup>+</sup> and megakaryocyte/erythrocyte progenitors (MEPs) defined as LK CD41<sup>−</sup>CD34<sup>−</sup>CD16/32<sup>−</sup>. Doublets and dead cells were excluded prior to analysis. (B) Graph showing the percentage of CMP, GMP, MEP in the BM of Apoe<sup>−/−</sup> mice fed a chow diet injected with PBS, BMDM–NG-exo or BMDM–HG-exo. A pool of four experiments is shown n = 19–23 mice per group. (C) Graph showing the percentage of CMP, GMP, MEP in the BM of Apoe<sup>−/−</sup> mice fed a Western diet injected with PBS, BMDM–NG-exo or BMDM–HG-exo. A pool of two experiments is shown n = 10–11 mice per group. (D and E) (D) Analysis of LSK, CMP, GMP, MEP populations in the spleen of Apoe<sup>−/−</sup> mice fed a chow diet injected with PBS, BMDM–NG-exo or BMDM–HG-exo and (E) Apoe<sup>−/−</sup> mice fed a Western diet. (F) Representative plots of flow cytometric analyses showing the gating strategy for circulating myeloid cells in Apoe<sup>−/−</sup> mice fed a chow diet injected with PBS, BMDM–NG-exo or BMDM–HG-exo and (G) Apoe<sup>−/−</sup> mice fed a Western diet. (H) Quantification of blood monocytes and neutrophils in chow diet fed mice and (H) Western diet fed Apoe<sup>−/−</sup> mice. Statistical analysis was performed using a two-way ANOVA with Sidak’s multiple comparisons post-test. *p< 0.05, **p< 0.01, ***p< 0.001. Data are represented as mean ± SEM.

Assessment of plasma EVs isolated from subjects with diabetes and atherosclerosis
In beginning to test the human relevance of exosomes produced under hyperglycemic conditions, we isolated circulating exosomes from 4 different groups of subjects: Healthy (Control-EVs), patients with peripheral arterial disease (PAD-EVs), patients with diabetes and no known coronary or peripheral artery disease (Diabetes-EVs) or diabetes associated with PAD (PAD + Diabetes-EVs) (Figure 4A). We used the terminology EVs to refer to human exosomes as there is more vesicle heterogeneity in particle sizes and contamination of other vesicular structures in human EVs as compared to EVs isolated from cultured cells. Plasma EVs were isolated using our C-DGUC method (Duong et al., 2019), the same method used to isolate BMDM-exosomes from conditioned culture medium.

To determine the fraction most enriched with EVs, we performed a Western blot analysis of the 12 collected fractions for the detection of EV-associated markers, CD63, CD9, and CD81 (Figure 4B). We observed that fractions 7 and 8 are the ones most enriched in exosomes with minimal plasma protein contaminants such as ApoA-I, and therefore these 2 fractions served for subsequent experiments.

NanoSight analysis of fraction 8 revealed a similar profile of EVs between all groups (Figure 4C) with particles ranging in sizes and a similar particle concentration per ml of plasma (Figure 4D). For the Control-EVs, we observed a mode size of 80 ± 11.74 nm, 102.1 ± 10.79 nm for PAD-EVs, 85.07 ± 5.41 nm for Diabetes-EVs and 64.44 ± 11.36 nm for PAD + Diabetes-EVs (Figure 4E). The measured protein concentration was similar between all groups (Figure 4F).

Diabetic plasma EVs communicate molecular changes in recipient macrophages
To explore biological functions of mouse macrophage exosomes and human diabetic plasma EVs in vitro, we performed RNA sequencing analysis of transcripts altered in recipient cells. Specifically, we tested naive murine BMDM exposed to PBS, BMDM–NG-exo and BMDM–HG-exo, as well as THP-1 cells exposed to human plasma EVs. Differential expression analysis revealed an upregulation of 57 genes and downregulation of 89 genes in BMDM exposed to BMDM–HG-exo compared to combined BMDM–NG-exo and PBS treated cells (Figure 5A). Furthermore, we noted that genes involved in pathways associated with cellular component organization and cell differentiation were upregulated, while hematopoiesis and immune response pathways were downregulated by BMDM–HG-exo (Figure 5B). We also noted an upregulation of Bcl2 expression in BMDM stimulated with BMDM–HG-exo, a key regulator of cellular apoptosis and critical modulator of HSC survival (Domen et al., 2000) and cellularity in atheroma (Bouchareychas et al., 2015). We also noted that BMDM–HG-exo reduced the expression of Abca1 that is central to promoting cholesterol efflux from macrophages and HSPC preventing their expansion and contribution to atherosclerosis (Yvan-Charvet et al., 2010). RNA Seq analysis of THP-1 cells exposed to circulating human EVs revealed...
differential expression of genes depending on the source of EVs (Figure 5C). EVs isolated from the plasma of diabetic subjects upregulated the expression of genes implicated in cellular proliferation and revealed a downregulation of genes implicated in the OXPHOS energy metabolism pathway and mitochondrial respiratory electron transport and ATP synthesis (Figure 5D) suggesting their capacity to disrupt mitochondrial complex function. Pathway analysis of PAD + Diabetes-EVs compared to Control-EVs revealed an upregulation of genes implicated in metabolic process and downregulation of genes implicated in leukocyte activation and cellular localization (Figure 5E). Together, our findings reveal that EVs produced in high glucose environments can substantially impact the expression of genes involved in metabolic and inflammatory pathway in recipient macrophages.

BMDM–HG-exo modulate macrophage energy metabolism

In following up on these observations, we examined whether BMDM–HG-exo can influence macrophage energy metabolism as we reported for exosomes produced by macrophages exposed IL-4 (Bouchareychas et al., 2020). First, we determined the oxygen consumption rate (OCR) including basal and maximal respiration, proton leak, ATP production and spare respiratory capacity in BMDM stimulated with PBS, BMDM–NG-exo or BMDM–HG-exo (Figure 6A). We observed an increase of maximal respiration, and spare respiratory capacity in cells exposed to BMDM–NG-exo compared to PBS control. However, we also observed that BMDM–HG-exo failed to increase OxPhos in recipient BMDM (Figure 6C).

Next, we tested the effect of BMDM–HG-exo on modulating the extracellular acidification rate (ECAR), an indicator of aerobic glycolysis (Figure 6B). Glycolysis rate, glycolytic capacity and glycolytic reserve were all significantly higher in macrophages stimulated with BMDM–HG-exo compared to PBS treated cells (Figure 6D). Of note, cells stimulated with BMDM–NG-exo also showed an increased glycolytic capacity and glycolytic reserve, but these changes were more notable in cells treated with BMDM–HG-exo.

Collectively, these findings demonstrate that BMDM–NG-exo upregulated both mitochondrial function and glycolysis to obtain the ATP necessary for their survival. However, BMDM–HG-exopromoted a metabolic switch among recipient cells toward a preferential use of glucose for energy production.

BMDM–HG-exo modulate cell proliferation in macrophages and myeloid progenitors

Having established their ability to modulate cellular energy metabolism, we next tested whether BMDM exosomes could impact cell proliferation. We performed an AlamarBlue assay with naive BMDM exposed to PBS, BMDM–NG-exo or BMDM–HG-exo and observed an increase in fluorescent signal demonstrating an increase in cell viability and therefore proliferation after 4 hr (Figure 7A) and 24 hr (Figure 7B) of BMDM–HG-exo treatment. Next, we measured cellular DNA content to detect the cell cycle distribution after treatment with PBS, BMDM–NG-exo or BMDM–HG-exo (Figure 7C). Our data consistently revealed an increase in the percentage of cells in phase S and G2/M (Figure 7D) among BMDM stimulated with BMDM–HG-exo.
compared to BMDM–NG-exo and PBS. These findings show that BMDM–HG-exo can serve to stimulate the proliferation of cultured macrophages. Next, we tested the impact that BMDM–HG-exo could exert to support hematopoietic stem cell function using a colony forming assay (CFU) assay (Figure 7E). Freshly isolated
BM cells exposed to BMDM–HG-exo displayed increased colony numbers compared to those exposed to PBS but not BMDM–NG-exo (Figure 7F) indicating that BMDM–HG-exo have a capacity to further enhance hematopoietic stem cell proliferation. Altogether, these data indicate that BMDM–HG-exo display a capacity to promote the proliferation of cells central to the pathogenesis of atherosclerosis.

Hyperglycemia dysregulates microRNA in myeloid cells and their EVs

Numerous studies have reported changes in circulating microRNA levels associated with accelerated atherosclerotic disease in diabetes (de Candia et al., 2017; Zampetaki et al., 2010). As we and others (Gaudreault et al., 2013; Nagareddy et al., 2013) observed that myeloid cells are impacted by hyperglycemia, we performed microRNA sequencing on Ly-6Chi monocytes and macrophages isolated from mouse models of hyperglycemia that included the STZ-induced and spontaneous Akita mouse models of diabetes.

Our findings revealed differential expression of 23 microRNA in Ly-6Ch+ monocytes sorted from the blood of STZ-treated mice compared to controls (Figure S3A). In the Akita mouse model, only 4 microRNA were differentially expressed in the Ly-6Ch+ monocytes compared to control with miR-486-5p found significantly upregulated (Figure S3B). In peritoneal macrophages isolated from the Akita mouse model, we also observed an upregulation of 24 microRNA and downregulation of 14 microRNA relative to wild-type mice (Figure S3C). Next, we analyzed microRNA expression profiles of BMDM exposed to normal or high glucose concentration. We observed a downregulation of 11 microRNA and an upregulation of 22 microRNA (Figure S3D).

A comparison of shared microRNA changes in peritoneal macrophages isolated from Akita mice and BMDM–HG cell population revealed an increase in levels of miR-126a-3p, miR-99b-5p, miR-16-5p and miR-423-3p in both hyperglycemic models. Next, we performed small RNA sequencing on both BMDM exosomes and human circulating EVs isolated from control and diabetic patients including those with established vascular disease. As shown Figure 9A, microRNA sequencing revealed 14 differentially expressed microRNA in BMDM–HG–exo compared to BMDM–NG–exo including 10 upregulated and 4 downregulated microRNA. Interestingly we observed that miR-486-5p was enriched in BMDM–HG–exo that parallel their increased expression in myeloid cells examined from hyperglycemic mouse models (Figure S3B). The increased miR-486-5p levels in BMDM–HG–exo compared to BMDM–NG–exo were further validated and confirmed using qRT-PCR (Figure 8B).

An analysis of microRNA levels in human circulating EVs showed few differences between Control-EVs and Diabetes-EVs (Figure 8C). However, we noted that PAD + Diabetes-EVs displayed 6 upregulated and 2 downregulated microRNA compared to Control-EVs (Figure 8D). Furthermore, some of these microRNA were also noted to be upregulated when comparing PAD + Diabetes-EVs and Diabetes-EVs (Figure 8E). Specifically, we noted that miR-486-5p was upregulated in PAD + Diabetes-EVs compared to Diabetes-EVs and Control-EVs. Furthermore, miR-486-5p was found to be upregulated in BMDM–HG–exo compared to BMDM–NG–exo (Figure 8A). Because miR-486-5p has been shown to reduce the expression of ABCA1 in THP-1 macrophages (Liu et al., 2016), we tested whether BMDM–HG–exo could reproduce this effect. Data shown in Figure 8F demonstrate that BMDM–HG–exo significantly reduce the expression of Abca1 mRNA in primary BMDM supporting the pro-atherogenic properties of these exosomes when infused into Apoe−/− mice.

Altogether, our observations demonstrate that hyperglycemia dysregulates microRNA levels in myeloid cells and their secreted exosomes and point to miR-486-5p as a candidate EV-associated microRNA that may play an important role in diabetic atherosclerosis acceleration.
DISCUSSION

Numerous studies recently revealed that EVs contribute to the pathogenesis of diabetes and cardiometabolic diseases, including via their microRNA cargo (Bei et al., 2017; Bouchareychas et al., 2020; Jansen et al., 2017; Krohn et al., 2016). Findings from our laboratory demonstrated that a select set of microRNA carried by macrophage EVs, also termed exosomes, impact the course of atherosclerosis in mice with...
Figure 7. BMDM–HG-exo modulate cell proliferation in macrophages and myeloid progenitors

(A and B) Measurement of fluorescent AlamarBlue signal in BMDM exposed to PBS, BMDM–NG-exo or BMDM–HG-exo during (A) 4 hr or (B) 24 hr.

(C) Flow cytometry histogram showing the gating strategy for the measurement of cell cycle distribution in BMDM after treatment with PBS, BMDM–NG-exo or BMDM–HG-exo for 4 hr.

(D) Quantitative analysis of cell cycle distribution. One representative experiment out of two experiments is shown.

(E and F) (E) Representative images of CFU assay (F) 2×10^4 BM cells from C57BL/6 mice were plated in Methylcellulose-based medium with recombinant cytokines for colony-forming unit (CFU) and treated every two days with PBS, BMDM–NG-exo or BMDM–HG-exo at a dose of 2×10^9 particles/ml. Pool of four experiments with 4 separate preparations of exosome were analyzed. Scale bars: 4.37 mm. Statistical analysis was performed using a two-way ANOVA with Sidak’s multiple comparisons post-test. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001. Data are represented as mean ± SEM.
whereas Ly-6Clow monocytes were increased in the same manner as neutrophils. In addition, stimulatory prop-
BMDM–HG-exo that was further increased in western diet fed mice. In Apoe
A key observation of this study was a significant increase of CMPs and GMPs in the BM of mice injected with
topoiesis and increased myeloid cell numbers in the circulation (Hazra et al., 2013; Kojima et al., 2014; Nagar-
our observations add to findings of several reports showing that diabetes is accompanied by altered hema-
mally regulated by cholesterol efflux mechanisms involving LXRs, ABCA1, ABCG1, and HDL (Wang et al.,
 results showed that BMDM–HG-exo decreased
expression in recipient BMDM cells. We could suggest that by decreasing
mice, BMDM–HG-exo increases hematopoiesis and myeloid
A key observation of this study was a significant increase of CMPs and GMPs in the BM of mice injected with
hyperglycemia (Bouchareychas et al., 2020). However, their signaling properties in complications of
diabetes, including atherosclerosis, remain incompletely understood. In light of the importance of the
macrophage in the pathogenesis of atherosclerosis in diabetes, there is a need to elucidate the role of
macrophage-derived EVs produced under metabolic stress.

Results of our study reveal a new appreciation for macrophage exosomes in the pathogenesis of diabetic
atherosclerosis. Specifically, our findings demonstrate that exosomes produced in a high-glucose environ-
ment, simulating human diabetic hyperglycemia levels of 450 mg/dL, induced metabolic reprogramming
of recipient cells. Specifically, we noted through bioenergetic studies that naive BMDM cells exposed to
BMDM–HG-exo increased glycolytic activity and displayed enhanced proliferation. Furthermore, we
observed that when infused into Apoe<sup>−/−</sup> mice, BMDM–HG-exo increases hematopoiesis and myeloid
cell numbers in the circulation that collectively led to larger numbers of macrophages in lesions along
with increased apoptotic areas and atherosclerosis progression.

A key observation of this study was an significant increase of CMPs and GMPs in the BM of mice injected with
BMDM–HG-exo that was further increased in western diet fed mice. In Apoe<sup>−/−</sup> mice fed a chow diet, while
BMDM-HG-exo were effective in driving hematopoiesis when compared to saline alone, no difference was
observed in mice injected with BMDM–HG-exo compared to BMDM–NG-exo showing that western diet
feeding could amplify the BMDM–HG-exo effect on CMP/GMP expansion. Numerous studies have re-
ported that the consumption of western diet triggers proliferative hematopoietic cell expansion that is nor-
mally regulated by cholesterol efflux mechanisms involving LXRs, ABCA1, ABCG1, and HDL (Wang et al.,
2007; Yvan-Charvet et al., 2007, 2010). Our results showed that BMDM–HG-exo decreased Abca1 mRNA
expression in recipient BMDM cells. We could suggest that by decreasing Abca1, BMDM–HG-exo further
amplified the HSPC expansion induced by the western diet consumption.

Our observations add to findings of several reports showing that diabetes is accompanied by altered hema-
topoiesis and increased myeloid cell numbers in the circulation (Hazra et al., 2013; Kojima et al., 2014; Nagar-
eddy et al., 2013). So far, this process has been shown to be driven by a systemic increase of S100A8/A9
produced by neutrophils, which signals through the receptor for advanced glycation end products (RAGE)
in hematopoietic progenitors cells (Nagarreddy et al., 2013) and by upregulating the expression of GLUT-1
on myeloid cells, enhancing glycolytic activity and proliferative signaling resulting in myelopoiesis (Flynn
et al., 2020). Although we did not explore this pathway in depth, RNA sequencing analysis of cultured macro-
phages exposed to BMDM–NG-exo or BMDM–HG-exo showed no differences in levels of RAGE or GLUT-1
gene expression. Surprisingly, we found that only mice fed a chow diet had an increase in hematopoietic pro-
genitors in the spleen after BMDM–HG-exo injections. In those mice, Ly-6Ch<sup>−</sup> monocyte levels were unchanged
whereas Ly-6Clow monocytes were increased in the same manner as neutrophils. In addition, stimulatory prop-
erties of high dietary cholesterol in Western diet fed mice could mask the added effects of the BMDM–HG-exo
on further driving myelopoiesis. Alternatively, larger numbers of BMDM–HG-exo may be required to drive he-
matopoiesis in mice fed a high fat diet as our injection paradigm consisted of only 4.5% of normal circulating
exosomes in mice (Huang et al., 2018). Regardless of their exact mode of function and effective concentration
dosage, we provide through this study the first evidence that macrophage-derived exosomes produced under
high glucose conditions can modulate hematopoiesis and myelopoiesis.

Along with their intrinsic capacity to increase hematopoietic progenitors and circulating leukocytes, we
observed that BMDM–HG-exo caused a substantial increase in atherosclerotic lesion area. We noted
that such changes included an increase of macrophage foam cell rich area and apoptotic cells in Apoe−/− mice injected with BMDM–HG-exo regardless of dietary challenge. As BMDM–HG-exo were able to increase proliferation in recipient cells, it is plausible that macrophage lesion area was elevated due to an increase in local macrophage proliferation. Indeed, macrophage proliferation locally in lesions has been shown to be a key event in atherosclerosis development (Robbins et al., 2013). Furthermore, results of our recent study of macrophage exosomes in atherosclerosis control demonstrated their ability to infiltrate the aorta of Apoe−/− mice (Bouchareychas et al., 2020).

Support for this line of reasoning comes from reports linking hyperglycemia to altered cell cycle regulation and proliferation (Nagy et al., 2019). While the underlying mechanisms are complex, studies have shown that they involve numerous pathways including AKT/mTOR activation (Lopez et al., 2013), epidermal growth factor (EGF), hypoxia-inducible factor-1/vascular endothelial growth factor-dependent (HIF-1/VEGF) pathways and apoptotic resistance pathway (Li et al., 2019). Such involvement in cellular reprogramming could explain the clinical observations linking high glucose levels with increased prevalence to developing cancer (Li et al., 2019).

In our study, we observed that BMDM–HG-exo could potently induce metabolic reprogramming in recipient cells by failing to increase oxidative phosphorylation, and rather increasing their glycolytic pathway consistent with an entry into the phase S of cell cycle. Importantly, we also observed by sequencing analysis that Homeodomain-interacting protein kinase 2 (HIPK2) was upregulated in BMDM stimulated with BMDM–HG-exo. HIPK2 is a co-regulator of a number of transcription factors and cofactors involved in DNA repair responses, cell proliferation and cell differentiation. Indeed, Hipk2−/− mice show defective hematopoiesis (Aikawa et al., 2006) and HIPK2 depletion by RNA interference has been shown to inhibits cell proliferation in primary BM (Iacovelli et al., 2009). Therefore, our data could support a scenario where BMDM–HG-exo upregulate hematopoiesis and cell proliferation through the HIPK2 signaling pathway that ensure DNA damage repair. Interestingly, we also noted an upregulation of Bcl2 in BMDM stimulated with BMDM–HG-exo. In addition to its role in regulating apoptosis, BCL-2 has also been found to be a key player in the regulation of mitochondrial function, hematopoiesis, metabolism, autophagy, cell cycle and DNA damage response (Glab et al., 2020). Transgenic mouse models that overexpress BCL-2 have increased numbers of HSC (Domen et al., 2000) and Ly-6Clow monocytes (Bouchareychas et al., 2015) consistent with findings of our study.

Beyond having characterized their cell-signaling properties, we identified several microRNAs that were enriched in BMDM–HG-exo compared to BMDM–NG-exo, including miR-486-5p. Interestingly, we found that PAD + Diabetes-EVs also displayed an increased level of miR-486-5p. In addition, miR-486-5p was enriched in Ly-6Clo monocytes sorted from the Akita mice.

To date, the pathological significance of miR-486-5p has not been fully elucidated and is subject to intense research in cancer biology due to its’s role in cell proliferation and cell cycle regulation. Indeed, studies have shown that miR-486-5p is central to the pathogenesis of chronic myeloid leukemia (CML) and aberrant hematopoiesis (Shaham et al., 2015; Wang et al., 2015).

Studies have also shown an increase of miR-486-5p in patients with coronary artery disease (Niculescu et al., 2015). More recently, miR-486-5p enriched in adipose-derived stem cell–EVs have been shown to accelerate the proliferation of skin fibroblasts (Lu et al., 2020). Furthermore, miR-486-5p was shown to reduce ABCA-1 expression in macrophages (Liu et al., 2016) that we reproduced through our studies of BMDM–HG-exo, which in this context could contribute to atherosclerosis acceleration in Apoe−/− mice treated with BMDM–HG-exo, and atherosclerosis in diabetic patients.

Regardless their exact mode of action, our findings uncovered that exosomes produced by macrophages exposed to high glucose concentrations and those isolated from the plasma of diabetic mice and human subjects carry increased levels of select microRNA including miR-486-5p that is associated with dysfunctional hematopoiesis and macrophage cholesterol homeostasis, could explain observations of increased circulating leukocytes and atherosclerosis in diabetic subjects. Further studies will be needed to quantify the proportion of macrophage derived EVs among the pool of EVs in human circulation to further validate whether exosomes produced by macrophages in vitro can reflect human physiology.
In summary, our findings reveal a new paradigm to account for experimental and clinical observations of accelerated atherosclerosis in diabetes. Our data show that detrimental properties of hyperglycemia on hematopoiesis can be communicated via exosomes produced by macrophages cultured in a high glucose environment. Mechanisms of action identified in this study include altered energy metabolism and cellular proliferation in target cells. Our data also suggests the possible existence of a feedforward mechanism by which metabolically stressed macrophages can communicate to the BM and spleen via exosomes to accentuate the supply of circulating monocytes and neutrophils in the setting of diabetes. While this process can be seen as detrimental in the context of diabetes, it is plausible that it evolved as a mechanism to help control the need for hematopoietic cell production in response to host infection or need for tissue repair. Our transcriptomics datasets also provide a rich resource for further investigation of the underlying biology of hyperglycemia mediated cellular dysfunction in diabetes. Furthermore, future studies of BMDM exosomes could reveal new opportunities to control cellular dysfunction and cardiovascular complications in diabetes.

Limitations of the study

Our approach of testing BMDM exosome function in vivo includes repeated infusions of an empirical number of BMDM-exosomes that may not accurately reflect physiological levels of exosomes produced by macrophage subtypes in mice. Furthermore, while our studies have identified microRNA cargo associated with exosomes produced by BMDM exposed to high glucose levels and EVs isolated from the plasma of diabetic human subjects, we do not in this study focus on elucidating specific molecular targets of such microRNA. Other possible exosomal cargo including proteins, lipids, and other RNA species that could impact cellular communication were not examined. The co-isolation of minor contaminants including protein aggregates and lipoproteins containing apoAI with EVs may add another level of complexity in the understanding of their function. Future studies will be required to fully understand the contribution of each component of the BMDM–exosomes and their respective targets in contributing to accelerated atherosclerosis in diabetes.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Animals
  - Primary cells used in this study
- METHOD DETAILS
  - Cell culture
  - EVs isolation and nanoparticle tracking analysis
  - Immunoblotting
  - Transmission electron microscopy
  - Exosomes labeling
  - RNA extraction, whole transcriptome library preparation, and Sequencing
  - NEXTFLEXSsmall RNLibrary Preparation
  - RNA-sequencing data analysis
  - Primary cell preparation and purification
  - Cholesterol
  - Atherosclerotic lesion analysis
  - Seahorse extracellular flux analysis
  - Glucose and ROS measurements
  - Cell proliferation
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102847.
ACKNOWLEDGMENTS

We thank staff at the University of California, San Francisco Functional Genomics Core for the human whole RNA sequencing analysis and staff at the University of California, Berkeley, Electron Microscope Laboratory for advice and assistance with electron microscopy sample preparation and imaging. We also thank Allen Chung, Michael Gomes and David Wong for technical assistance. This work was supported by grants from the NIH, United States, including R01HL133575 and UG3CA241703 from the Extracellular RNA Communication Consortium Common Fund, supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director. Funding was also provided by the American Heart Association, United States, Grant-in-Aid 16GRNT27640007 to R.L.R., and U.S. Department of Veterans Affairs, United States Merit Award grant 1101BX003928-01A2 to R.L.R. who is the recipient of a Research Career Scientist award (# IK6BX005692) from the Department of Veterans Affairs, United States. L.B. was supported by a postdoctoral fellowship from the American Heart Association, United States (19POST34380672). Authors have no conflicts of interest to declare.

R.L.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

AUTHOR CONTRIBUTIONS

L.B. designed and performed experiments, collected and analyzed data, and graphed and interpreted the results. P.D. and T.A.P. isolated macrophage exosomes. E.A., B.M., R.R., and K.V.K.-J. performed unbiased microRNA sequencing and analysis. M.N. provided assistance with mice and NanoSight analysis. R.Y. and H.N. provided guidance with the study of hematopoiesis. W.J.G. provided de-identified human plasma samples. L.B. and R.L.R. wrote the manuscript with contributions from all authors. R.L.R. conceived and supervised the project.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: December 9, 2020
Revised: May 16, 2021
Accepted: July 9, 2021
Published: August 20, 2021

REFERENCES

Aikawa, Y., Nguyen, L.A., Isozo, K., Takakura, N., Tagata, Y., Schmitz, M.L., Koseki, H., and Kitabayashi, J. (2006). Roles of HIPK1 and HIPK2 in AML-1- and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J. 25, 3955–3965.

Bej, Y., Das, S., Rodostenous, R.S., Holvoet, P., Vanhaverbeke, M., Monteiro, M.C., Monteiro, V.V.S., Radosinska, J., Bartekova, M., Jansen, F., et al. (2017). Extracellular vesicles in cardiovascular theranostics. Theranostics 7, 4168–4182.

Bouchareychas, L., Duong, P., Covarrubias, S., Alsop, E., Phu, T.A., Chung, A., Gomes, M., Wong, D., Meechoovet, B., Capilli, A., et al. (2020). Macrophage exosomes resolve atherosclerosis by regulating hematopoiesis and inflammation via MicroRNA cargo. Cell Rep. 32, 107881.

Bouchareychas, L., Grossinger, E.M., Kang, M., Qiu, H., and Adamopoulos, I.E. (2017). Critical role of LTβR4/LBT1 in IL-23-induced synovial inflammation and osteoclastogenesis via NF-kappaB. J. Immunol. 198, 452–460.

Bouchareychas, L., Pirault, J., Saint-Charles, F., Deswaerte, V., Le Roy, T., Jessup, W., Giral, P., Le Goff, W., Hubyi, T., Gautier, E.L., et al. (2015). Promoting macrophage survival delays progression of pre-existing atherosclerotic lesions through macrophage-derived apoE. Cardiovasc. Res. 108, 111–123.

Burke, A.P., Kolodgie, F.D., Zieske, A., Fowler, D.R., Weber, D.K., Varghese, P.J., Fab, A., and Virmani, R. (2004). Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol. 24, 1266–1271.

Creager, M.A., Luscher, T.F., Cosentino, F., and Beckman, J.A. (2003). Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation 108, 1527–1532.

de Candia, P., Spinetti, G., Specchia, C., Sangalli, E., La Sala, L., Uccellatore, A., Lupini, S., Genovese, S., Matarese, G., and Ceriello, A. (2017). A unique plasma microRNA profile defines type 2 diabetes progression. PLoS One 12, e0188980.

Domen, J., Cheshier, S.H., and Weissman, I.L. (2000). The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential. J. Exp. Med. 191, 253–264.

Duong, P., Chung, A., Bouchareychas, L., and Raffai, R.L. (2019). Cushioned-Density Gradient Ultracentrifugation (C-DGUC) improves the isolation efficiency of extracellular vesicles. PLoS One 14, e0215324.

Flynn, M.C., Kraakman, M.J., Tikellis, C., Lee, M.K.S., Hanssen, N.M.J., Kamoun, H.L., Pickering, R.J., Dragoljevic, D., Al-Sharea, A., Barrett, T.J., et al. (2020). Transient intermittent hyperglycemia accelerates atherosclerosis by promoting myelopoiesis. Circ. Res. 127, 877–892.

Freeman, D.W., Noren Hooten, N., Eitan, E., Green, J., Mode, N.A., Bodoagi, M., Zhang, Y., Lehmann, E., Zonderman, A.B., Biragyn, A., et al. (2018). Altered extracellular vesicle concentration, cargo, and function in diabetes. Diabetes 67, 2377–2388.

Garcia-Conteras, M., Shah, S.H., Tamayo, A., Robbins, P.D., Golberg, R.B., Mendez, A.J., and Ricordi, C. (2017). Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes. Sci. Rep. 7, 5998.
Hyperglycemia impairs atherosclerosis repair potential and increasing inflammatory monocyte generation in a murine model. Diabetologia 56, 644–653.

Huang, C., Fisher, K.P., Hammer, S.S., Navitskaya, E., 2020. Plasma microvesicles contribute to macrovascular damage in diabetic retinopathy by activating the classical complement pathway. Diabetes 67, 1639–1649.

Iacovelli, S., Ciuffini, L., Lazzari, C., Bracaglia, G., Rinaldo, C., Prodosimo, A., Bartolazzi, A., Sacchi, A., and Soddu, S. 2009. HIPPO2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Prolif. 42, 373–384.

Jansen, F., Nickeng, G., and Werner, N. 2017. Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology. Circ. Res. 120, 1649–1657.

Kanter, J.E., Hsu, C.C., and Bornfeld, K.E. 2020. Monocytes and macrophages as protagonists in vascular complications of diabetes. Front Cardiovasc. Med. 7, 10.

Kanter, J.E., Kramer, F., Barnhart, S., Duggan, J.M., Shimizu-Albergine, M., Kothari, V., Chait, A., Bourman, S.D., Hamerman, J.A., Hansen, B.F., et al. 2018. A novel strategy to prevent advanced atherosclerosis and lower blood glucose in a mouse model of metabolic syndrome. Diabetes 67, 946–959.

Kojima, H., Kim, J., and Chan, L. 2014. Emerging roles of hematopoietic cells in the pathobiology of diabetic complications. Trends Endocrinol. Metab. 25, 178–187.

Krohn, J.B., Hutchesson, J.D., Martinez-Martinez, E., and Akawa, E. 2016. Extracellular vesicles in cardiovascular calcification: expanding current paradigms. J. Physiol. 594, 2895–2903.

Lakhter, A.J., and Sims, E.K. 2015. Minireview: emerging roles for extracellular vesicles in diabetes and related metabolic disorders. Mol. Endocrinol. 29, 1535–1548.

Li, W., Zhang, X., Sang, H., Zhou, Y., Shang, C., Wang, Y., and Zhu, H. 2019. Effects of hyperglycemia on the progression of tumor diseases. J. Exp. Clin. Cancer Res. 38, 327.

Liu, D., Zhang, M., Xie, W., Lan, G., Cheng, H.P., Gong, D., Huang, C., Li, Y.C., Yao, F., Tan, Y.L., et al. 2016. miR-486 regulates cholesterol efflux by targeting HAT1. Biochem. Biophys. Res. Commun. 472, 418–424.

Lopez, R., Arumugam, A., Joseph, R., Monga, K., Boopathan, T., Aguilo, P., Gutierrez, C., Nandy, S., Subramani, R., de la Rosa, J.M., et al. 2013. Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin/IGF1R signaling and activation of AKT/mTOR. PLoS One 8, e79708.

Lu, Y., Wen, H., Huang, J., Liao, P., Liao, H., Tu, J., and Zeng, Y. 2020. Extracellular vesicle-enclosed miR-486-5p mediates wound healing with adipose-derived stem cells by promoting angiogenesis. J. Cell Mol. Med. 24, 9590–9604.

Mathieu, M., Martin-Jaular, L., Lavieu, G., and Thery, C. 2019. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17.

Moreno, P.R., Murcia, A.M., Palacios, I.F., Leon, M.M., Bernardi, V.H., Fuster, V., and Fallon, J.T. 2000. Coronary composition and macrophage infiltration in arteriectomized specimens from patients with diabetes mellitus. Circulation 102, 2180–2184.

Murphy, A.J., Akhtari, M., Tolani, S., Pagler, T., Biil, N., Kuo, C.L., Wang, M., Sanson, M., Abramowicz, S., Welch, C., et al. 2011. ApoE regulates hematopoietic stem cell proliferation, monocytoesis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 121, 4318–4341.

Nagareddy, P.R., Murphy, A.J., Stirzaker, R.A., Hu, Y., Yu, S., Miller, R.G., Ramkhalawon, B., Distel, E., and Steeel, J. 2013. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 17, 695–708.

Nagy, T., Fisi, V., Frank, D., Katai, E., Nagy, Z., and Miseta, A. 2019. Hyperglycemia-induced aberrant cell proliferation, Atematoblast challenge mediated by protein O-GlcNAc modification. Cells 8, 999.

Niculescu, L.S., Simionescu, N., Sanda, G.M., Carnuta, M.G., Stanco, C.S., Popescu, A.C., Popescu, M.R., Vlad, A., Dimulescu, D.R., Simionescu, M., et al. 2015. miR-486 and miR-92a identified in circulating HDL discriminate between stable and vulnerable coronary artery disease patients. PLoS One 10, e0140958.

Robbins, C.S., Chudnovskiy, A., Rauch, P.J., Figueiredo, J.I., Iwamoto, Y., Gorbatov, R., Eztrodt, M., Weber, G.F., Ueno, T., van Rooijen, N., et al. 2012. Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation 125, 364–374.

Robbins, C.S., Hilgendorf, I., Weber, G.F., Theurl, I., Iwamoto, Y., Figueiredo, J.L., Gorbatov, R., Sukhova, G.K., Gerhardt, L.M., Smyth, D., et al. 2013. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 19, 1166–1172.

Shaham, L., Vendramini, E., Ge, Y., Goren, Y., Birger, Y., Tijssen, M.R., McNulty, M., Geron, I., Schwartzman, O., Goldberg, L., et al. 2015. MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. Blood 125, 1292–1301.

Sorrentino, T.A., Duong, P., Bouchareychas, L., Chen, M., Chung, A., Schaller, M.S., Oskowski, A., Raffai, R.L., and Conte, M.S. 2018. Circulating exosomes from patients with peripheral arterial disease influence vascular cell migration and contain distinct microRNA cargo. JVS Vasc. Sci. 1, 28–41.

Swirska, F.K., Libby, P., Akawa, E., Alcaide, P., Luscinskas, F.W., Wessleder, R., and Pittet, M.J. 2007. Ly-6Ch monocytes dominate hypercholesterolemia-associated monocytoesis and give rise to macrophages in atheroma. J. Clin. Invest 117, 195–205.

Thery, C., Ostrowski, M., and Segura, E. 2009. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immuniul. 9, 581–593.

Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., and Lotvall, J.O. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–667.

Wang, L.S., Li, B., Chu, S., Shiang, K.D., Li, M., Sun, H.Y., Xu, J., Xiao, F.J., Sun, G., et al. 2015. MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood 125, 1302–1313.

Wang, X., Collins, H.L., Ranalletta, M., Fuki, I.V., Billheimer, J.T., Rothblat, G.H., Tall, A.R., and Rader, D.J. 2007. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest 117, 2216–2224.

Wen, M.H., Song, Z.J., Huang, C.H., Liang, Q., Xu, M.X., Wang, L.G., Zhang, W.T., Lu, P., Zhan, B.M., Yu, L.L., et al. 2018. Plasma exosomes induced by remote ischaemic preconditioning attenuate myocardial ischaemia/reperfusion injury by transferring miR-24. Cell Death Dis. 9, 320.

Xu, J., Murphy, S.L., Kochanek, K.D., and Arias, E. 2016. Mortality in the United States, 2015 (NCHS Data Brief), pp. 1–8.

Yvan-Charvet, L., Plegler, T., Gautier, E.L., Avagyan, S., Siny, R.L., Han, S., Welch, C.L., Wang, N., Randolph, G.J., Snoeck, H.W., et al. 2010. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328, 1689–1693.

Yvan-Charvet, L., Ranalletta, M., Wang, N., Han, S., Terasaka, N., Li, R., Welch, C., and Tall, A.R. 2007. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest 117, 3900–3908.

Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., Mayr, A., Weger, S., Oberhollenzer, F., Bonora, E., et al. 2010. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 107, 810–817.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE                        | SOURCE                      | IDENTIFIER                  |
|--------------------------------------------|-----------------------------|-----------------------------|
| Antibodies                                 | Abcam                       | Cat# ab92726, RRID:AB_10561589 |
| Immunoblotting: Rabbit monoclonal anti-CD9 | Abcam                       | Cat# ab10286, RRID:AB_2069009 |
| Immunoblotting: Mouse monoclonal anti-CD81 | Santa Cruz Biotechnology    | Cat# sc-166029, RRID:AB_2275892 |
| Immunoblotting: Mouse monoclonal anti-CD63 | BD Biosciences              | Cat# 556019, RRID:AB_396297  |
| Immunoblotting: Rabbit polyclonal anti-Calnexin | Abcam                       | Cat# sc-376818, RRID:AB_2797313 |
| Immunoblotting: Mouse monoclonal anti-GM130 | BD Biosciences              | Cat# 610823, RRID:AB_398142  |
| Immunoblotting: Rabbit monoclonal anti-Flotillin-1 | Cell Signaling Technology    | Cat# 18634, RRID:AB_2773040   |
| Immunoblotting: Mouse monoclonal anti-Alix | Santa Cruz Biotechnology    | Cat# sc-53540, RRID:AB_673819  |
| Immunoblotting: Mouse monoclonal anti-APOA1 | Santa Cruz Biotechnology    | Cat# sc-516102, RRID:AB_2687626 |
| Immunoblotting: mouse IgG kappa binding protein (m-IgG kBP)-HRP | BioLegend                   | Cat# A10547, RRID:AB_2534046  |
| Flow Cytometry: Biotin anti-mouse/human CD45R/B220 antibody | BioLegend                   | BioLegend Cat# 103204, RRID:AB_312989 |
| Flow Cytometry: Biotin anti-mouse CD4 antibody | BioLegend                   | Cat# 100508, RRID:AB_3127111  |
| Flow Cytometry: Biotin anti-mouse CD8 antibody | BioLegend                   | Cat# 100704, RRID:AB_312743   |
| Flow Cytometry: Brilliant Violet 421 anti-mouse CD16/32 antibody | BioLegend                   | Cat# 101332, RRID:AB_2650889  |
| Flow Cytometry: Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) antibody | BioLegend                   | Cat# 108404, RRID:AB_313369   |
| Flow Cytometry: PE/Cy7 anti-mouse CD150 (SLAM) antibody | BioLegend                   | Cat# 115914, RRID:AB_439797   |
| Flow Cytometry: Biotin anti-mouse TER-119/Erythroid Cells antibody | BioLegend                   | Cat# 116204, RRID:AB_313705   |
| Flow Cytometry: Brilliant Violet 510 anti-mouse CD41 antibody | BioLegend                   | Cat# 133923, RRID:AB_2564013  |
| Flow Cytometry: Biotin anti-mouse CD127 (IL-7Ra) antibody | BioLegend                   | Cat# 135006, RRID:AB_2126118  |
| Flow Cytometry: PE anti-mouse CD115 (CSF-1R) antibody | BioLegend                   | Cat# 135505, RRID:AB_1917254  |
| Flow Cytometry: FITC anti-mouse Ly-6C antibody | BioLegend                   | Cat# 128006, RRID:AB_1186135  |
| Flow Cytometry: PerCP/Cyanine5.5 anti-mouse/human CD11b antibody | BioLegend                   | Cat# 101228, RRID:AB_893232  |
| Flow Cytometry: APC anti-mouse CD45 antibody | BioLegend                   | Cat# 103112, RRID:AB_312977   |
| Flow Cytometry: c-Kit Monoclonal Antibody (2B8), APC-Cyanine7 | Thermo Fisher Scientific    | Cat# A15423, RRID:AB_2534436  |
| Flow Cytometry: CD34 Monoclonal Antibody (RAM34), FITC | Thermo Fisher Scientific    | Cat# 11-0341-85, RRID:AB_465022 |
| Flow Cytometry: Ly-6A/E (Sca-1) Monoclonal Antibody (D7), PE | Thermo Fisher Scientific    | Cat# 12-5981-83, RRID:AB_466087 |
| Flow Cytometry: CD48 Monoclonal Antibody (HM48-1), APC | Thermo Fisher Scientific    | Cat# 17-0481-82, RRID:AB_469408 |
| Flow Cytometry: CD135 (Flt3) Monoclonal Antibody (A2F10), PerCP-eFluor 710 | Thermo Fisher Scientific    | Cat# 46-1351-82, RRID:AB_10733393 |
| Flow Cytometry: BV786 Streptavidin | BD Biosciences              | Cat# 563858, RRID:AB_2869529  |
| TruStain FcX Antibody | BioLegend                   | Cat# 101320, RRID:AB_1574975  |
| Rat Anti-Mouse Macrophages/Monocytes Monoclonal antibody, Unconjugated, Clone moma-2 | Cedarlane                   | Cat# CL89154, RRID:AB_10086520 |
| Cleaved Caspase-3 (Asp175) Antibody | Cell Signaling Technology   | Cat# 9661, RRID:AB_2341188   |
| Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 | Thermo Fisher Scientific    | Cat# A-21206, RRID:AB_2535792  |
| Donkey anti-Rat IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 594 | Thermo Fisher Scientific    | Cat# A-21209, RRID:AB_2535795  |

(Continued on next page)
Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Chemicals, peptides, and recombinant proteins | | |
| iScript Reverse Transcription Supermix | Bio-Rad Laboratories | Cat# 1708841 |
| Fast SYBR Green Master Mix | Applied Biosystems | Cat# 4385614 |
| miRCURY LNA RT Kit | Qiagen | Cat# 339340 |
| miRCURY LNA SYBR Green PCR Kit | Qiagen | Cat# 339347 |
| 4–20% Mini-PROTEAN TGX Stain-Free Protein Gels | Bio-Rad Laboratories | Cat# 4568094 |
| 4x Laemmli Sample Buffer | Bio-Rad Laboratories | Cat# 1610747 |
| Amersham ECL Prime Western Blotting Detection Reagent | GE Healthcare | Cat# RPN2232 |
| Immun-Blot PVDF Membrane | Bio-Rad Laboratories | Cat# 1620177 |
| Penicillin-Streptomycin | Gibco | Cat# 15140122 |
| Dulbecco’s Modified Eagle’s Medium | Corning | Cat# 10-014-CV |
| RPMI 1640 | Coming | Cat# 10-040-CV |
| Phorbol 12-Myristate 13-Acetate | Fisher Scientific | Cat# BP685-1 |
| Recombinant Murine M-CSF | PeproTech | Cat# 315-02 |
| D-(+)-Glucose solution | Sigma-Aldrich | Cat# G8769-100ML |
| D-Mannitol | MP Biomedicals | Cat# 02152540-CF |
| Trypsin-EDTA (0.05%) | Gibco | Cat# 25300054 |
| GlutaMAX | Gibco | Cat# 35050061 |
| RBC Lysis Buffer (10X) | BioLegend | Cat# 420301 |
| CountBright Absolute Counting Beads | Thermo Fisher Scientific | Cat# C36950 |
| RD Western Diet | Research Diets | Cat# D12079B |
| Teklad Global Diets | Envigo | Cat# 2016 |
| OptiPrep density gradient medium | Sigma-Aldrich | Cat# D1556-250ML |
| Tissue-Tek O.C.T Compound | Sakura FineTek | Cat# 4583 |
| Oil Red O | Sigma-Aldrich | Cat# O1391 |
| Mayer’s Hematoxylin | Thermo Fisher Scientific | Cat# 72804 |
| VECTASHIELD Antifade Mounting Medium with DAPI | Vector Laboratories | Cat# H-1200 |
| Sucrose, 20% Sterile Solution | VWR | Cat# E543-100ML |
| 10X Tris-EDTA, pH 7.4 | Fisher Scientific | Cat# BP24771 |
| RNase A/T1 Mix | Thermo Fisher Scientific | Cat# EN0551 |
| Seahorse XF base medium | Agilent | Cat# 103335-100 |
| Seahorse XF 100 mM pyruvate solution | Agilent | Cat# 103578-100 |
| Seahorse XF 200 mM glutamine solution | Agilent | Cat# 103579-100 |
| MethoCult™ GF | StemCell Technologies | Cat# M3434 |
| Streptozocin | Sigma-Aldrich | Cat# 50130 |
| alamarBlue | Bio-Rad Laboratories | Cat# BUF012B |
| Live Cell Imaging Solution | Thermo Fisher Scientific | Cat# A14291DJ |
| DiR (DiIC18(7)(1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindotricarbocyanine Iodide)) | Invitrogen | Cat# D12731 |

Critical commercial assays

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| miRNeasy Mini Kit | Qiagen | Cat# 217004 |
| Quant-iT RiboGreen RNA Assay Kit | Thermo Fisher Scientific | Cat# R11490 |
| Slide-A-Lyzer MINI Dialysis Device, 10K MWCO | Thermo Fisher Scientific | Cat# 88404 |
| Seahorse XFe24 FluxPaks | Agilent | Cat# 102340-100 |
| Seahorse XF Glycolysis Stress Test Kit | Agilent | Cat# 103020-100 |

(Continued on next page)
Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Seahorse XF Cell Mito Stress Test Kit | Agilent | Cat# 103015-100 |
| Seahorse XFe24 Cell Culture Microplates | Agilent | Cat# 100777-004 |
| MitoSOX™ Red Mitochondrial Superoxide Indicator | Thermo Fisher Scientific | Cat# M36008 |
| CM-H2DCFDA (General Oxidative Stress Indicator) | Thermo Fisher Scientific | Cat# C6827 |
| CellROX Deep Red Flow Cytometry Assay Kit | Thermo Fisher Scientific | Cat# C10491 |
| FixCycle violet stain | Thermo Fisher Scientific | Cat# F10347 |
| Fixation/Permeabilization Solution Kit | BD Biosciences | Cat# 554714 |
| Qubit Protein Assay Kit | Thermo Fisher Scientific | Cat# Q33211 |
| PKH26 Red Fluorescent cell Linker kit | Sigma-Aldrich | Cat# PKH26GL-1KT |
| Wako Diagnostics Total Cholesterol E | Fisher Scientific | Cat# 999-02601 |
| Sigma Glucose (GO) Assay Kit | Sigma-Aldrich | Cat# GAGO20-1KT |
| Fragment Analyzer RNA Kits | Agilent | Cat# DNF-472-0500 |
|Fragment Analyzer DNA/NGS Kits | Agilent | Cat# DNF-474-0500 |
| Universal Plus mRNA-Seq with NuQuant | TECAN | Cat# 0520 |
| MiniSeq High Output Reagent Kit | Illumina | Cat# FC-420-1001 |
| HiSeq 3000/4000 SBS Kit | Illumina | Cat# FC-410-1001 |
| TURBO DNA-free™ Kit | Thermo Fisher Scientific | Cat# AM1907 |
| RNA Clean & Concentrator-5 | Zymo Research | Cat# R1016 |
| High Sensitivity RNA ScreenTape | Agilent | Cat# 5067-5579 |
| High Sensitivity RNA ScreenTape Sample Buffer | Agilent | Cat# 5067-5580 |
| SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian Components | Takara Bio | Cat# 634418 |
| SMARTer RNA Unique Dual Index Kit | Takara Bio | Cat# 634452 |
| High Sensitivity D1000 ScreenTape | Agilent | Cat# 5067-5584 |
| High Sensitivity D1000 Sample Buffer | Agilent | Cat# 5067-5603 |
| KAPA SYBR FAST Universal qPCR Kit | Kapa Biosystems | Cat# KK4824 |
| NovaSeq 6000 S1 Reagent Kit | Illumina | Cat# 20012864 |
| PhiX Control v3 | Illumina | Cat# FC-110-3001 |
| BioAnalyzer High Sensitivity DNA Analysis | Agilent | Cat# 5067-4626 |
| NEXTflex Small RNA Library Prep Kit v3 | Perkin Elmer | Cat# NOVA-5132-06 |

**Deposited data**

- Mouse small RNA -Seq: This paper | GEO Study Accession: GSE162958
- Mouse long RNA-Seq: This paper | GEO Study Accession: GSE162961
- Human small RNA -Seq: This paper | dbGaP Study Accession: phs002401.v1.p1

**Experimental models: cell lines**

- THP-1 | UCSF- Cell and Genome Engineering Core | N/A

**Experimental models: organisms/strains**

- Mouse: B6.129P2-Apoetm1Unc/J | Jackson Laboratories | JAX:002052
- Mouse: C57BL/6-In2Akita/J | Jackson Laboratories | JAX:003548
- Mouse: C57BL6/J | Jackson Laboratories | JAX:00664

**Oligonucleotides**

- Mouse B2m F primer: CTGCTACGTAACACACAGTCCACCC | This paper | N/A
- Mouse B2m R primer: CATGATGCTTGATCACATGTCTCG | This paper | N/A
- Mouse Gapdh F primer: TGAAGCAGGCATCTGAGGG | This paper | N/A

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Robert L. Raffai (robert.raffai@ucsf.edu).

Materials availability
BMDM-derived exosomes generated in this study will be made available on request, but we may require a payment and/or a completed Materials Transfer Agreement if there is potential for commercial application.

Data and code availability

- RNA-seq data have been deposited at GEO accession number: GSE162958 for small RNA and GEO: GSE162961 for long RNA and human data are accessible through the accession number dbGaP: phs002401.v1.p1 and are publicly available as of the date of publication. Accession numbers are listed in the key resources table.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

### Software and algorithms

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Mouse Gapdh R primer: CGAAGGTGGAAGAGTGGGAG | This paper | N/A |
| Mouse Abca1 F primer: ACCTGGAGAGAAGCTTTCAATGA | This paper | N/A |
| Mouse Abca1 R primer: GTTCAGGTGTACACACTCCATGA | This paper | N/A |

| RESOURCE or NAME       | SOURCE | IDENTIFIER |
|------------------------|--------|------------|
| FlowJo v10.6.2         | FlowJo | https://www.flowjo.com/ |
| ImageJ                 | NIH    | https://imagej.nih.gov/ij/ |
| Photoshop CC           | Adobe  | https://www.adobe.com/products/photoshop.html |
| Prism 7                | GraphPad | https://www.graphpad.com/scientific-software/prism/ |
| 2100 Expert Bioanalyzer | Agilent | https://www.agilent.com/en/product/automated-electrophoresis/bioanalyzer-systems/bioanalyzer-software/2100-expert-software-228259 |
| XFe Wave software      | Agilent | https://www.agilent.com/en/product/cell-analysis/cell-analysis-software/data-analysis/wave-desktop-2-6 |
| NTA 3.2                | Malvern Panalytical | https://www.malvernpanalytical.com/en/support/product-support/software/NanoSight-NTA-software-update-v3-2 |
| NIS Elements BR 4.3    | Nikon  | https://www.nikon.com/products/microscope-solutions/support/download/software/mgsfw/nis_br_v4300164.htm |
| ZEN 3.0 Software       | Zeiss  | https://www.zeiss.com/microscopy/us/products/microscope-software/zen.html |
| R (version 3.5.0)      | R Core Team | https://www.R-project.org/ |
| STAR aligner software version 2.7.2b | STAR | http://code.google.com/p/rna-star/ |
**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Animals**
All animal experiments were approved by the Institutional Animal Care and Use Committee at the VA Medical Center. Approximately 8 to 10-week-old male C57BL/6J (000664) wild type (WT), 8 to 10-week-old male C57BL/6-Ins2Akita/J (003548) and 25 to 30-week-old male Apoetm1Unc/J (Apoe^{-/-}) mice on C57BL/6 background were used in this study. All mice were obtained from The Jackson Laboratory (Sacramento, CA), bred and housed in specific pathogen–free conditions in the Animal Research Facility at the San Francisco VA Medical Center.

To induce diabetes, 10-week-old WT mice were given daily intraperitoneal injections of STZ (50 mg/kg body weight) dissolved in 0.05 M sodium citrate buffer for 5 days. Controls were injected with an equivalent volume of sodium citrate buffer. Diabetes induction was monitored by blood glucose measurements sampled from the tail vein (accu-Check).

Because wild-type mice do not spontaneously develop atherosclerosis, we choose the Apoetm1Unc/J mouse model which is the most widely used pre-clinical model of atherosclerosis to study the effect of exosomes produced in high glucose in vivo.

The use of western diet feeding is recognized to drive the process of hematopoiesis in this model. Therefore, we choose to use both chow and western fed Apoetm1Unc/J mouse model to distinguish the BMDM-exo effect from the priming effect of the western diet on HSPC expansion. Ten-week-old male Apoetm1Unc/J mice were fed a Western diet (Research Diets) for 10 weeks or 26-week old male Apoetm1Unc/J fed a chow diet were used for hematopoiesis and atherosclerosis assessment.

In this study, exosomes were infused intraperitoneally (IP) as we previously reported that IP-infused exosomes could target hematopoietic compartments as well as aorta (Bouchareychas et al., 2020). Exosomes were infused three times a week for 4 weeks with saline (PBS) or with 1x10^{10} BMDM-derived exosomes. Mice that appeared unhealthy (body weight <2 SD below average) or with skin lesions were excluded.

**Primary cells used in this study**
Bone marrow-derived macrophage (BMDM) and hematopoietic stem cells (HSC) were derived from male C57BL/6J mice ranging from 8 to 12 weeks of age.

**METHOD DETAILS**

**Cell culture**
Murine BMDM were obtained as described previously (Bouchareychas et al., 2017). Briefly, BM cells were flushed from the tibia and femurs of 8-week-old WT C57BL/6 mice. Cells were cultured in Dulbecco’s Modified Eagle’s Medium (Corning) supplemented with 10% fetal bovine serum (GIBCO), 1% GlutaMax (GIBCO), and 1% penicillin-streptomycin (GIBCO) and differentiated with 25 ng/ml mouse M-CSF (Peprotech) for 6 days. For exosome isolation, BMDM were cultured in exosome-free media (EFM) prepared by ultracentrifugation for 18 h at 100,000 x g (Type 45 Ti rotor, Beckman Coulter) and filtration (0.2 mm). BMDM were washed two times with PBS and cultured for 24 h with 19.5mM glucose (Sigma-Aldrich) to produce BMDM–HG-exo or 19.5mM Mannitol (MP Biomedicals) for BMDM–NG-exo. For in vitro experiments, BMDM were dispersed into 12-well culture plates (Corning) at a concentration of 0.3 x10^6 cells/well and stimulated with BMDM–NG-exo or BMDM–HG-exo for 24 h at a concentration of 2x10^9 particles per ml. The THP-1 human monocytic cell line was maintained in RPMI 1640 media supplemented with 10% FBS and 1% penicillin-streptomycin (GIBCO) and differentiated into macrophages using a treatment with phorbol-12-myristate acetate (50 ng/ml) for 48h followed by 24 h incubation in RPMI complete medium.

For CFUs assay, 2 x10^4 total BM cells isolated from the legs and hips of 8-week-old male WT mice were cultured in Methylcellulose-based medium with a recombinant cytokine mix (StemCell Technologies). Cells were treated with PBS, BMDM–NG-exo or BMDM–HG-exo every two days at a dose of 2 x10^9 particles/ml. Number of the colonies were quantified after 12 days of culture using a Zeiss Axio Observer microscope and ZEN 3.0 Software.
**EVs isolation and nanoparticle tracking analysis**

EVs were isolated from conditioned cell culture medium or from 1ml of human plasma by Cushioned-Density Gradient Ultracentrifugation (C-DGUC) as previously described (Bouchareychas et al., 2020). We used the terminology EVs to refer to human exosomes as there is more vesicle heterogeneity in particle sizes and contamination for other vesicular structures in human EVs as compared to EVs isolated from cultured cells.

To produce BMDM exosomes, BM cells were plated onto a 150 mm round dishes at a density of 5x10^6 cells per dish. Cell culture supernatant (20 ml) was harvested from an average of 20 plates with 5x10^6 cells/plate and an average viability of 96% for BMDM. The collected media were subjected to 400 x g centrifugation for 10 min at 4°C followed by 2000 x g centrifugation for 20 min at 4°C and filtered (0.2 mm).

Human plasma was first centrifuged at 1,500 x g for 10 minutes at 4°C and 1 ml was diluted in 38.5 mL of cold PBS. Cell culture supernatant or diluted plasma was centrifuged on a 60% iodixanol cushion (Sigma-Aldrich) at 100,000 x g for 3 h (Type 45 Ti or Type 50.2 Ti rotor, Beckman Coulter). The bottom 3 mL was then collected and underlaid below a step density gradient composed of three 3 ml layers (5%, 10%, 20% w/v OptiPrep iodixanol) in a Beckman Coulter Ultra-Clear centrifuge tube. The density gradient was subsequently spun at 100,000 x g for 18 h at 4°C (SW 40 Ti rotor, Beckman Coulter). Subsequently, twelve 1 mL fractions were collected starting from the top of the tube. Fractions 7 and 8 of the gradient were dialyzed in PBS with the Slide-A-Lyzer MINI Dialysis Device (Thermo Fisher Scientific) and used for subsequent experiments and analyses. NanoSight LM14 (Malvern Instruments, Westborough, MA) was used to measure EVs size and concentration using a 488-nm detection wavelength. The analysis settings were optimized and kept identical for each sample, with a detection threshold set at 3, three videos of 1min each were analyzed to give the mean, mode, median, and estimated concentration for each particle size. Samples were diluted in 1:100 or 1:200 PBS and measured in triplicates. Data were analyzed with the NTA 3.2 software. All the EVs samples were stored at 4°C and used within one month after their isolation.

**Immunoblotting**

For western blot analysis, an equal volume of the EV fractions were mixed with Laemmli buffer (Bio-Rad Laboratories) and boiled at 95°C for 5 minutes. Samples were then loaded on a 10% SDS-PAGE gel and transferred onto PVDF membrane (Bio-Rad Laboratories). The membranes were blocked with 5% non-fat milk dissolved in PBS for 1 h and then probed with primary antibodies overnight at 4°C (primary antibodies: anti-CD9 (1:100, Abcam), anti-Flotillin (1:500, Cell Signaling), anti-Alix (1:100, Santa Cruz Biotechnology), anti-Calnexin (1:500, Abcam), anti-GM130 (1:250, BD Biosciences), anti-CD81 (1:100, Santa Cruz Biotechnology), anti-CD63 (1:100, BD Pharmingen), anti-APOA1 (1:500, Santa Cruz Biotechnology). After 4 washes in PBS containing 0.1% Tween (PBST), membranes were incubated with corresponding HRP-conjugated secondary antibodies: anti-mouse IgG-HRP (1:1000, Santa Cruz Biotechnology), anti-rabbit IgG-HRP (1:1000, Thermo Fisher Scientific) or anti-rat IgG-HRP (1:1000, Thermo Fisher Scientific) for 1h and washed in PBST. Signals were visualized after incubation with Amersham ECL Prime substrate and imaged using an ImageQuant LAS 4000.

**Transmission electron microscopy**

An assessment of exosome morphology was assessed by Electron microscopy by loading 7x10^8 particles onto a glow discharged 400 mesh Formvar-coated copper grid (Electron Microscopy Sciences). The nanoparticles were left to settle for two minutes, and the grids were washed four times with 1% Uranyl acetate. Excess Uranyl acetate was blotted off with filter paper. Grids were then allowed to dry and subsequently imaged at 120kV using a Tecnai 12 Transmission Electron Microscope (FEI).

**Exosomes labeling**

Fluorescently labelled BMDM-derived exosomes were generated using PKH26 (Sigma Aldrich) or with DiR (DiIC18(7) (1,1’-Diocatadecyl-3,3’,3’Tetramethylindotricarbocyanine Iodide) (Invitrogen) according to the manufacturer’s instructions. Briefly, PKH26 or DiR dye was added to the 3mL iodixanol cushion layer containing exosome or to 3ml of PBS to achieve a final concentration of 3.5 μM for PKH26 and 1 μM for DiR and incubated for 5 min and 20 min respectively at room temperature. Next, we loaded the labeled cushion layer below an iodixanol step gradient as described in the EVs isolation section. Free dye and non-specific protein-associated dye was eliminated from labeled exosomes or from PBS control during this separation step. BMDM cells were then incubated with 2x10^9 PKH26-labeled exosomes for 2 h, washed 3 times with PBS and imaged using a Nikon Eclipse Ni microscope and data were analyzed using ImageJ.
Three groups of 25 weeks old male Apoe\(^{-/-}\) mice of similar weight and fed a chow diet were injected with PBS or \(1 \times 10^{10}\) BMDM-NG-DiR exosomes, either intravenously (IV) via the retro-orbital plexus or intraperitoneally (I.P.). Subsequently, a similar blood volume was collected from each mouse at the 2, 4-, 8- and 24-h timepoints post-injection and IR intensity was detected using the Odyssey Infrared Imaging System and Image Studio software.

RNA extraction, whole transcriptome library preparation, and Sequencing

Exosomes preparations were treated with 0.4 mg/ml of RNase A/T1 Mix (Thermo Fisher Scientific) for 20 min at 37°C before RNA extraction. Total RNA isolated from cells and exosomes was purified using the miRNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. RNA was quantified using Nanodrop or Quant-IT RiboGreen RNA Assay Kit (Thermo Fisher Scientific) and reverse transcribed using the iScript Reverse Transcription Supermix (Bio-Rad Laboratories) for mRNA or the miRCURY LNA RT Kit (Qiagen) for microRNA analysis. PCR reactions were performed using the Fast SYBR Green Master Mix (Applied Biosystems) for mRNA or the miRCURY LNA SYBR Green PCR Kit (Qiagen) for microRNA and run on a QuantStudio 7 Flex Real-Time PCR System. Ct values were normalized to the housekeeping gene Gapdh and B2m for mouse mRNA. For microRNA expression, UniSp6 was used as a spike-in control (Qiagen). The following real time primers were used: 5’-ACCTGAGAGAAGCTTTCAATGA-3’ (forward) and 5’-GTTCAGGTTGACACTCCATGA-3’ (reverse) for mouse ABCA1; 5’-CTGCTACGTAACACAGCTTC CACCC-3’ (forward) and 5’-CATGATGCTTGATCACATGTCTCG-3’ (reverse) for mouse B2m; 5’-TGAAG CAGGACATGAGAGGAGAGGGAGA-3’ (forward) and 5’-CGAAGGTGGAAGGTGGGAG-3’ (reverse) for mouse Gapdh. primers for miR-486-5p were purchased from Qiagen.

For sequencing analysis, isolated RNA sample was DNase treated with TURBO DNA-free (Thermo Fisher), then purified and concentrated with Zymo RNA Clean & Concentrator – 5 (Zymo Research). The RNA was measured for quantity with Quant-IT Ribogreen RNA Assay (Thermo Fisher) and quality with Agilent High Sensitivity RNA Screen Tape and buffer (Agilent). For mouse RNA samples, an indexed, Illumina-compatible, double-stranded cDNA whole transcriptome library was synthesized from 10ng of total RNA with Takara Bio’s SMARTer Stranded Total RNA-Seq kit v2 Pico Input Mammalian (Takara Bio) and SMARTer RNA Unique Dual Index Kit (Takara Bio). Library preparation included RNA fragmentation (94°C for 4 min), cDNA synthesis, a 5-cycle indexing PCR, ribosomal cDNA depletion, and a 12-cycle enrichment PCR. Each library was measured for size with Agilent’s High Sensitivity D1000 ScreenTape and reagents (Agilent) and concentration with KAPA SYBR FAST Universal qPCR Kit (Kapa Biosystems). Libraries were then combined into an equimolar pool which was also measured for size and concentration. The pool was clustered onto a flowcell (Illumina) with a 1% v/v PhiX Control v3 spike-in (Illumina) and sequenced on Illumina’s NovaSeq 6000 at a final flowcell concentration of 400pM. The first and second reads were each 100 bases.

For human RNA samples, the integrity of total RNA was verified on Fragment Analyzer (Agilent), and only RNA with RQN number of above 8 was used for library constructions. A starting quantity of 70 ng of total RNA was used according to vendor instructions with Universal plus mRNA with NuQuant (TECAN), final library PCR amplification was 16 cycles. After library completion, individual libraries were pooled equally by volume, quantified on Fragment Analyzer (Agilent). Quantified library pool was diluted to 1nM and sequenced on Miniseq (Illumina) to check for quality of reads. Finally, individual libraries were normalized according to Illumina’s Miniseq output reads, specifically by % protein coding genes. The library pool was clustered onto 4 lanes of Illumina’s HiSeq4000 single end read (SE) 50 (Illumina).

NEXTFLEX Small RNA Library Preparation

Small RNA libraries were generated using NEXTflex Small RNA Library Prep Kit v3 (PerkinElmer) following the manufacturer’s instructions using gel purification without adapter inactivation and 16 cycles of PCR amplification. Following PCR amplification, libraries between 140 and 160bp in size were gel purified using 6% TBE gels followed by ethanol precipitation and resuspension in 20ul of ultra-pure water.

RNA-sequencing data analysis

The raw sequence image files from the Illumina HiSeq in the form of bcl files were converted to the fastq format using bcl2fastq v.2.19.1.403 and checked for quality to ensure the quality scores did not deteriorate at the read ends.
For small RNA data processing, the Bioo Scientific NEXTflex adapters and random 4bp ends were clipped from the reads using cutadapt v.1.14. Reads shorter than 15 nts were discarded and after adaptor trimming, the 30 bases below a quality score of 30 were also trimmed. The reads are first mapped to a library of UniVec contaminants, a collection of common vector, adaptor, linker and PCR primer sequences collated by the NCBI. They are then mapped to mouse rRNA sequences obtained from NCBI. Finally, small RNA mapping and annotation was done using sRNABench (v.3-3.2) where reads are mapped to the mouse genome (GRCm38) and transcriptome using a transcriptome which contains all ensemble genes plus annotations for microRNAs, as obtained for miRBase (v.22). Alignment files are then processed by sRNABench into miRNA counts matrices for further analysis.

For mouse whole transcriptome data processing, the SMARTer Total RNA pico v2 reads are quality filtered and trimmed as recommended by Takara Bio with the removal of the first 3 bases of read2. After trimming and filtering reads are genome and transcriptome mapped using STAR (v. 2.5.3a). Aligned BAM files are converted into gene counts matrices for further analysis using FeatureCounts (v.2.0.1), using read2 as the sense strand. For RNAseq analysis, differential expression was conducted using the DESeq2 package (version 1.20.0) in R (version 3.5.0) for all gene expression analyses. The raw read counts for the samples were normalized using the median ratio method (default in DESeq2). The significant differentially expressed genes (by Benjamini-Hochberg adjusted p values) are reported in the paper. Heatmaps were created using the pheatmap (v.1.0.10) package in R.

GO analyses were performed using PANTHER GO-slim Biological Process and DAVID with a FDR threshold at ≤ 0.05 or <0.01 as indicated on each figure.

For human whole sequencing analysis, reads were aligned to the human genome GRCh38 and quantified using the STAR aligner software version 2.7.2b. Differential expression analysis was performed in the R computing environment version 3.6.1 using the software DESeq2 version 1.26. FDR-corrected p-values were used to evaluate significant differences between experimental groups using a significance threshold of 0.05. A minimum differential expression of log2 fold change +/- 1 was also used to determine significance. Gene ontology analyses were conducted using PANTHER GO-slim Biological Process.

**Primary cell preparation and purification**

Leukocytes subsets and hematopoietic stem and progenitors cells (HSPC) were identified as previously described (Bouchareychas et al., 2020). Briefly, blood was drawn by retro-orbital puncture into EDTA-coated tubes. Erythrocytes were lysed in RBC lysis buffer (BioLegend). Samples were then centrifuged at 300 x g and 4°C and incubated with TruStain FcX (BioLegend) for 10 min at 4°C in FACS buffer before staining with appropriate Abs: CD11b (clone M1/70), Ly-6C (clone HK1.4), CD115 (clone AFS98) CD45 (clone 30-F11) (all BioLegend) for 30 min at 4°C. The antibody dilutions ranged from 1:200 to 1:100. For microRNA sequencing analysis, a total of 50,000 Ly-6C<sup>hi</sup> monocytes were sorted from the blood of diabetic WT mice treated with STZ or Akita mice and their respective non-diabetic controls using a FACSARia IIIU cell sorter (BD Biosciences). Peritoneal cells were collected by lavage with 10 ml cold PBS using a 16-G needle. Cells were then plated in 6-well plates and harvested 6 h later.

For HSPC staining, murine femora were excised, flushed with 10 ml of sterile PBS and filtered through 40 μm filters. Cells were centrifuged at 300 x g and 4°C for 5 min and the red blood cells were lysed. Cells were washed, re-centrifuged and stained in FACS buffer containing a lineage-marker cocktail of biotinylated anti-CD4 (RM4-5), -CD8 (53-6.7), -B220/CD45RA (RA3-6B2), -TER-119 (TER-119), -Gr-1 (RB6-8C5), and -CD127 (IL-7Ra/ATR734) antibodies (all from BioLegend). These cells were then stained with anti-CD34 (RAM34, eBioscience), anti-CD150 (TC15-12F12.2, BioLegend), anti-CD48 (HM48-1, Invitrogen), anti-Sca-1 (D7, Invitrogen), anti-CD135 (A2F10, Invitrogen), anti-c-Kit (2B8, Life Technologies), anti-CD16/32 (93, BioLegend), anti-CD41 (MWMReg30, BioLegend) and streptavidin-BV786 (BD Biosciences). Sca1<sup>+</sup> c-Kit<sup>+</sup> (LSK) Flt3<sup>+</sup> CD34<sup>-</sup> was used as HSC-gating parameters. MPP1 population was defined as CD34<sup>+</sup> CD150<sup>-</sup> CD48<sup>-</sup> cells, MPP2 as CD34<sup>+</sup> LSK CD150<sup>+</sup> CD48<sup>+</sup> cells, MPP3 as CD34<sup>+</sup> LSK CD150<sup>-</sup>CD48<sup>+</sup> cells and MPP4 as CD34<sup>+</sup> LSK Flt3<sup>+</sup> CD150<sup>+</sup>CD48<sup>+</sup> cells. Common myeloid progenitors (CMPs) were gated as Sca1<sup>-</sup> c-Kit<sup>+</sup> CD41<sup>-</sup> CD34<sup>+</sup> CD16/32<sup>-</sup>. The granulocyte/macrophage progenitors (GMPs) was defined as Sca1<sup>-</sup> c-Kit<sup>+</sup> CD41<sup>-</sup> CD34<sup>+</sup> CD16/32<sup>+</sup> and megakaryocyte/erythrocyte progenitors (MEPs) as Sca1<sup>-</sup> c-Kit<sup>+</sup> CD41<sup>-</sup> CD34<sup>-</sup> CD16/32<sup>-</sup>. Doublets, dead cells, and Lin<sup>-</sup> cells were excluded prior gating analysis. Absolute numbers of cells were calculated using CountBright Absolute Counting Beads (Thermo Fisher Scientific).
Scientific). Data were acquired on an LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo v10.6.2 (FlowJo).

**Cholesterol**

Plasma total cholesterol was quantified using the Wako Total E cholesterol kit following the manufacturer’s instructions.

**Atherosclerotic lesion analysis**

Aortic root sections were stained and quantified as previously described (Bouchareychas et al., 2015). Hearts were excised following perfusion with PBS, fixed in 10% formalin, incubated overnight in 20% sucrose and embedded in OCT. For Apoe<sup>−/−</sup> mice, hearts were sectioned with a cryostat (10 μm), stained with oil red O (Sigma-Aldrich) and counterstained with modified Mayer’s hematoxylin (Thermo Fisher Scientific). Lesion area was quantified by averaging six sections that were spaced 50 μm apart, starting from the base of the aortic root. Necrotic core area was measured by determining the acellular region (DAPI negative) in each plaque. For macrophage staining, sections were labeled with a primary rat anti-mouse MOMA-2 antibody (Cedarlane labs) and detected with an AlexaFluor 594 donkey anti-rat IgG antibody (Thermo Fisher Scientific). To assess apoptotic cells in lesion, sections were stained for cleaved caspase-3 (Cell Signaling, 1/200) staining followed by AlexaFluor 488 donkey anti-rabbit IgG (Thermo Fisher Scientific). Total cleaved caspase 3 positive area was calculated and divided by the total atherosclerotic plaque area measured by ORO in serial sections. Images were captured with a Nikon Eclipse Ni and a Zeiss Observer microscope, analyzed using NIS-Elements and ZEN 3.0 Software. Analyses were performed in a blinded manner.

**Seahorse extracellular flux analysis**

BMDM were plated at 60,000 cells/well into XFe24 cell culture microplates (Agilent) and incubated overnight at 37°C and 5% CO₂. The following day, BMDM were stimulated with PBS, BMDM–NG-exo or BMDM–HG-exo for 24 h. For the cell Mito stress test, cells were washed with Seahorse XF base medium (Agilent) supplemented with 10 mM glucose (Sigma-Aldrich), 1 mM pyruvate (Agilent) and 2 mM glutamine (GIBCO) and incubated for 1 h at 37°C without CO₂. For the Glycolysis stress test, cells were placed in Seahorse XF base medium supplemented with 2 mM glutamine. OCR and ECAR were measured using the mitochondrial stress test kit (Agilent) and Glycolysis stress kit with the Seahorse XFe-24 Bioanalyzer (Agilent) and were analyzed using XFe Wave software. All OCR/ECAR measurements were normalized to cell count.

**Glucose and ROS measurements**

Glucose was quantified in the culture supernatant of the BMDM exposed to 5.5mM or 25mM glucose using the Glucose (GO) Assay Kit (Sigma-Aldrich) following the manufacturer’s instructions.

BMDM were plated in 96 well plates and treated with elevated glucose levels (25 mM glucose) or osmotic normal glucose levels (5.5 mM glucose +19.5 mM mannitol) for 24 h. Culture medium was then removed, cells washed with PBS, then incubated with MitoSOX (5 μM final, Invitrogen) or CM-H2DCFDA (10 μM, Invitrogen) in Live Cell Imaging Solution (Invitrogen) for 30 min at 37°C. Cells were washed twice and the fluorescence signal was measured in a microplate reader (CM-H2DCFDA 488/543 nm, MitoSOX 510/580 nm). For CellROX analysis, BMDM were plated in 12-well plates at 0.3 x10⁶ cells/ml with 5.5mM or 25mM glucose for 24 h. Thirty minutes before the end of the stimulation, CellROX (5 μM) was added directly into the cell culture medium and incubated at 37°C for 30 min. Cells were washed, removed from plates with cellstripper (Corning), pelleted at 300 x g for 5 min, resuspended and subjected to FACS analysis using CytoFlex S cytometer (Beckman-Coulter).

**Cell proliferation**

The proliferation of cultured BMDM was measured at 4 h and 24 h after exosome stimulation using the alamarBlue assay (Bio-Rad Laboratories). BMDM were plated in 96 well plates and treated with PBS, BMDM–NG-exo or BMDM–HG-exo for 24 h with 10% (vol/vol) AlamarBlue in culture medium and incubated at 37°C, 5% CO₂. Fluorescence intensity was read using a microplate spectrofluorometer at excitation 560 nm and emission 590 nm. Cell-cycle analysis was performed using FxCycle violet stain (Invitrogen). BMDM were plated in 12 well plates at 0.3 x10⁶ cells/ml and treated with PBS, BMDM–NG-exo or
BMDM–HG-exo (2x10⁹ particle/ml) for 4 h. Cells were washed with warmed PBS, removed from plates with cellstripper (Corning), pelleted at 300 x g for 5 min, resuspended in fixation/permeabilization solution (BD Bioscience) for 15 min. Cells were washed with Perm/Wash Buffer (BD Bioscience), centrifuged at 300 x g for 5 min and resuspended in Perm/Wash Buffer containing FxCycle violet stain, incubated for 30 min and subjected to FACS analysis.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis was performed using GraphPad Prism v8.4.3, and the tests used were unpaired, two-tailed, Student’s t test (two groups) and one-way analysis of variance (ANOVA) with post-tests as indicated in figure legends for multiple groups. *p < 0.05, **p < 0.01, ***p < 0.001 ****p < 0.0001. All error bars represent the mean ± the standard error of the mean (SEM unless stated). All experiments were repeated at least twice or performed with independent samples.